Treatment of methicillin-resistant staphylococcus aureus: Vancomycin and beyond

Seminars in Respiratory and Critical Care Medicine

Volumn 36, Issue 1, 2015, Pages 17-30

  Holmes, Natasha E ^a   Tong, Steven Y C ^b   Davis, Joshua S ^b,c   Hal, Sebastiaan J Van ^d,e  

^a Department of Infectious Diseases   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

daptomycin; individualized dosing; linezolid; lipoglycopeptides; methicillin resistant Staphylococcus aureus; vancomycin; lactams

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAROLINE; CEFTOBIPROLE; CREATININE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DRUG THERAPY; LINEZOLID; ORITAVANCIN; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG EFFECTS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG POTENCY; DRUG THERAPY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DRUG EFFECTS; DRUG THERAPY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCAL INFECTIONS; THERAPEUTIC USE; VANCOMYCIN;

EID: 84964284160     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1397040     Document Type: Article

References (180)

1. Boucher H. W.; Talbot G. H.; Bradley J. S.; et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis: 2009; 48 1 1 12
2. Sievert D. M.; Ricks P.; Edwards J. R.; et al. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol: 2013; 34 1 1 14
3. Lodise T. P.; McKinnon P. S. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis: 2005; 52 2 113 122
4. Dantes R.; Mu Y.; Belflower R.; et al. Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med: 2013; 173 21 1970 1978
5. Barna J. C.; Williams D. H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol: 1984; 38 339 357
6. Howden B. P.; Davies J. K.; Johnson P. D.; Stinear T. P.; Grayson M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev: 2010; 23 1 99 139
7. Craig W. A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am: 2003; 17 3 479 501
8. Rybak M. J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis: 2006; 42 01 S35 S39
9. Rybak M.; Lomaestro B.; Rotschafer J. C.; et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm: 2009; 66 1 82 98
10. Moise P. A.; Forrest A.; Bhavnani S. M.; Birmingham M. C.; Schentag J. J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm: 2000; 57 02 S4 S9
11. Moise-Broder P. A.; Forrest A.; Birmingham M. C.; Schentag J. J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet: 2004; 43 13 925 942
12. Avent M. L.; Vaska V. L.; Rogers B. A.; et al. Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J: 2013; 43 2 110 119
13. Neely M. N.; Youn G.; Jones B.; et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother: 2014; 58 1 309 316
14. Leu W. J.; Liu Y. C.; Wang H. W.; Chien H. Y.; Liu H. P.; Lin Y. M. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis: 2012; 16 11 e804 e810
15. Kullar R.; Davis S. L.; Taylor T. N.; Kaye K. S.; Rybak M. J. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy: 2012; 32 3 195 201
16. Liu C.; Bayer A.; Cosgrove S. E.; et al. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis: 2011; 52 3 e18 e55
17. Patel N.; Pai M. P.; Rodvold K. A.; Lomaestro B.; Drusano G. L.; Lodise T. P. Vancomycin: we can't get there from here. Clin Infect Dis: 2011; 52 8 969 974
18. Nunn M. O.; Corallo C. E.; Aubron C.; Poole S.; Dooley M. J.; Cheng A. C. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother: 2011; 45 6 757 763
19. Wang J. T.; Fang C. T.; Chen Y. C.; Chang S. C. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother: 2001; 47 2 246
20. Mohammedi I.; Descloux E.; Argaud L.; Le Scanff J.; Robert D. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents: 2006; 27 3 259 262
21. Thomson A. H.; Staatz C. E.; Tobin C. M.; Gall M.; Lovering A. M. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother: 2009; 63 5 1050 1057
22. James J. K.; Palmer S. M.; Levine D. P.; Rybak M. J. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother: 1996; 40 3 696 700
23. Wysocki M.; Delatour F.; Faurisson F.; et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother: 2001; 45 9 2460 2467
24. Cataldo M. A.; Tacconelli E.; Grilli E.; Pea F.; Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother: 2012; 67 1 17 24
25. Ingram P. R.; Lye D. C.; Tambyah P. A.; Goh W. P.; Tam V. H.; Fisher D. A. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother: 2008; 62 1 168 171
26. Prakash V.; Lewis J. S. II, Jorgensen J. H. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother: 2008; 52 12 4528
27. van Hal S. J.; Barbagiannakos T.; Jones M.; et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother: 2011; 66 10 2284 2287
28. Holmes N. E.; Turnidge J. D.; Munckhof W. J.; et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother: 2013; 57 4 1654 1663
29. Rybak M. J.; Vidaillac C.; Sader H. S.; et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol: 2013; 51 7 2077 2081
30. Neuner E. A.; Casabar E.; Reichley R.; McKinnon P. S. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis: 2010; 67 3 228 233
31. Ghosh N.; Chavada R.; Maley M.; van Hal S. J. Impact of source of infection and vancomycin AUC0-24 /MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect: 2014
32. Kullar R.; Davis S. L.; Levine D. P.; Rybak M. J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis: 2011; 52 8 975 981
33. Zelenitsky S.; Rubinstein E.; Ariano R.; et al. Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents: 2013; 41 3 255 260
34. Brown J.; Brown K.; Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother: 2012; 56 2 634 638
35. Gawronski K. M.; Goff D. A.; Brown J.; Khadem T. M.; Bauer K. A. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther: 2013; 35 6 772 779
36. Jung Y.; Song K. H.; Cho Je.; et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents: 2014; 43 2 179 183
37. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. CLSI document M07-A7. 7th ed. Wayne, PA CLSI: 2006
38. van Hal S. J.; Lodise T. P.; Paterson D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis: 2012; 54 6 755 771
39. Holmes N. E.; Turnidge J. D.; Munckhof W. J.; et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis: 2011; 204 3 340 347
40. Aguado J. M.; San-Juan R.; Lalueza A.; et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis: 2011; 17 6 1099 1102
41. van Hal S. J.; Jones M.; Gosbell I. B.; Paterson D. L. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS ONE: 2011; 6 6 e21217
42. van Hal S. J.; Paterson D. L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother: 2011; 55 1 405 410
43. Horne K. C.; Howden B. P.; Grabsch E. A.; et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother: 2009; 53 8 3447 3452
44. Peleg A. Y.; Monga D.; Pillai S.; Mylonakis E.; Moellering R. C. Jr, Eliopoulos G. M. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis: 2009; 199 4 532 536
45. Soriano A.; Marco F.; Martínez J. A.; et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis: 2008; 46 2 193 200
46. Thwaites G. E.; Edgeworth J. D.; Gkrania-Klotsas E.; et al. UK Clinical Infection Research Group. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis: 2011; 11 3 208 222
47. Bailey E. M.; Rybak M. J.; Kaatz G. W. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother: 1991; 35 6 1089 1092
48. Svetitsky S.; Leibovici L.; Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother: 2009; 53 10 4069 4079
49. Yoon Y. K.; Park D. W.; Sohn J. W.; et al. Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-associated methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother: 2014; 58 317 324
50. Chang H. J.; Hsu P. C.; Yang C. C.; et al. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study. J Antimicrob Chemother: 2012; 67 3 736 741
51. Chen K. Y.; Chang H. J.; Hsu P. C.; et al. Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin-resistant Staphylococcus aureus pneumonia. J Microbiol Immunol Infect: 2013; 46 3 210 216
52. Higgins D. L.; Chang R.; Debabov D. V.; et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2005; 49 3 1127 1134
53. Saravolatz L. D.; Stein G. E.; Johnson L. B. Telavancin: a novel lipoglycopeptide. Clin Infect Dis: 2009; 49 12 1908 1914
54. Belley A.; McKay G. A.; Arhin F. F.; et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother: 2010; 54 12 5369 5371
55. McKay G. A.; Beaulieu S.; Arhin F. F.; et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother: 2009; 63 6 1191 1199
56. Bozdogan B.; Esel D.; Whitener C.; Browne F. A.; Appelbaum P. C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother: 2003; 52 5 864 868
57. Leuthner K. D.; Cheung C. M.; Rybak M. J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother: 2006; 58 2 338 343
58. Rybak J. M.; Barber K. E.; Rybak M. J. Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother: 2013; 14 14 1919 1932
59. Rodvold K. A.; McConeghy K. W. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis: 2014; 58 01 S20 S27
60. Leonard S. N.; Szeto Y. G.; Zolotarev M.; Grigoryan I. V. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents: 2011; 37 6 558 561
61. Moellering R. C. Jr. Tedizolid: a novel oxazolidinone for Gram-positive infections. Clin Infect Dis: 2014; 58 01 S1 S3
62. Rubinstein E.; Lalani T.; Corey G. R.; et al. ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis: 2011; 52 1 31 40
63. Corey G. R.; Kollef M. H.; Shorr A. F.; et al. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother: 2014; 58 4 2030 2037
64. Stryjewski M. E.; Lentnek A.; O'Riordan W.; et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis: 2014; 14 289
65. Stryjewski M. E.; O'Riordan W. D.; Lau W. K.; et al. FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis: 2005; 40 11 1601 1607
66. Stryjewski M. E.; Graham D. R.; Wilson S. E.; et al. Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis: 2008; 46 11 1683 1693
67. Zhanel G. G.; Calic D.; Schweizer F.; et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs: 2010; 70 7 859 886
68. Burke S. L.; Rose W. E. New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother: 2014; 15 4 483 491
69. Jones R. N.; Sader H. S.; Flamm R. K. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis: 2013; 75 3 304 307
70. Citron D. M.; Tyrrell K. L.; Goldstein E. J. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis: 2014; 79 4 438 440
71. Boucher H. W.; Wilcox M.; Talbot G. H.; Puttagunta S.; Das A. F.; Dunne M. W. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med: 2014; 370 23 2169 2179
72. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment, 2013. Available at: http://www.fda.gov/downloads/Drugs/../Guidances/ucm071185.pdf. Accessed August 15, 2014
73. Ambrose P. G.; Drusano G. L.; Craig W. A. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis: 2012; 54 03 S220 S228
74. Tice A. Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis: 2012; 54 03 S239 S243
75. Arhin F. F.; Sarmiento I.; Belley A.; et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother: 2008; 52 5 1597 1603
76. Karaoui L. R.; El-Lababidi R.; Chahine E. B. Oritavancin: an investigational lipoglycopeptide antibiotic. Am J Health Syst Pharm: 2013; 70 1 23 33
77. Lin G.; Pankuch G.; Appelbaum P. C.; Kosowska-Shick K. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents. Antimicrob Agents Chemother: 2014; 58 10 6251 6254
78. Arhin F. F.; Sarmiento I.; Moeck G. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. Int J Antimicrob Agents: 2014; 44 1 65 68
79. Mendes R. E.; Sader H. S.; Flamm R. K.; Farrell D. J.; Jones R. N. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother: 2014; 58 5 2921 2924
80. Corey G. R.; Kabler H.; Mehra P.; et al. SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med: 2014; 370 23 2180 2190
81. Chambers H. F. Pharmacology and the treatment of complicated skin and skin-structure infections. N Engl J Med: 2014; 370 23 2238 2239
82. Chang F. Y.; Peacock J. E. Jr, Musher D. M.; et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore): 2003; 82 5 333 339
83. Stryjewski M. E.; Szczech L. A.; Benjamin D. K. Jr.; et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis: 2007; 44 2 190 196
84. Kim S. H.; Kim K. H.; Kim H. B.; et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother: 2008; 52 1 192 197
85. Schweizer M. L.; Furuno J. P.; Harris A. D.; et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis: 2011; 11 279
86. Chan K. E.; Warren H. S.; Thadhani R. I.; et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol: 2012; 23 9 1551 1559
87. Chambers H. F. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin Microbiol Infect: 2006; 12 02 17 22
88. Kosowska-Shick K.; McGhee P. L.; Appelbaum P. C. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother: 2010; 54 5 1670 1677
89. Steed M. E.; Rybak M. J. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy: 2010; 30 4 375 389
90. Richter S. S.; Heilmann K. P.; Dohrn C. L.; et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother: 2011; 55 9 4154 4160
91. Pfaller M. A.; Flamm R. K.; Sader H. S.; Jones R. N. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis: 2014; 78 4 422 428
92. Flamm R. K.; Sader H. S.; Jones R. N. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis: 2014; 78 4 437 442
93. Werth B. J.; Steed M. E.; Kaatz G. W.; Rybak M. J. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the seesaw effect Antimicrob Agents Chemother: 2013; 57 6 2664 2668
94. Werth B. J.; Barber K. E.; Ireland C. E.; Rybak M. J. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother: 2014; 58 6 3177 3181
95. Werth B. J.; Sakoulas G.; Rose W. E.; Pogliano J.; Tewhey R.; Rybak M. J. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother: 2013; 57 1 66 73
96. File T. M. Jr, Wilcox M. H.; Stein G. E. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis: 2012; 55 03 S173 S180
97. Arshad S.; Hartman P.; Zervos M. J. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther: 2014; 12 7 727 729
98. Pasquale T. R.; Tan M. J.; Trienski T. L.; File T. M. Jr. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother: 2013; Y0000000156
99. Lin J. C.; Aung G.; Thomas A.; Jahng M.; Johns S.; Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother: 2013; 19 1 42 49
100. Casapao A. M.; Davis S. L.; Barr V. O.; et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother: 2014; 58 5 2541 2546
101. Tattevin P.; Boutoille D.; Vitrat V.; et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicenter observational study. J Antimicrob Chemother: 2014; 69 7 2010 2013
102. Polenakovik H. M.; Pleiman C. M. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents: 2013; 42 5 450 455
103. Sakoulas G.; Moise P. A.; Casapao A. M.; et al. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline. Clin Ther: 2014
104. Jain R.; Chan J. D.; Rogers L.; Dellit T. H.; Lynch J. B.; Pottinger P. S. High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy: 2014; 34 7 758 763
105. Griffiths C. L.; Gutierrez K. C.; Pitt R. D.; Lovell R. D. Eosinophilic pneumonia induced by ceftaroline. Am J Health Syst Pharm: 2014; 71 5 403 406
106. Desai K. R.; Burdette S. D.; Polenakovik H. M.; Hagaman J.; Pleiman C. M. Ceftaroline-induced eosinophilic pneumonia. Pharmacotherapy: 2013; 33 7 e166 e169
107. Espedido B. A.; Jensen S. O.; van Hal S. J. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother: 2014;; November 17 epub ahead of print
108. Saravolatz S. N.; Martin H.; Pawlak J.; Johnson L. B.; Saravolatz L. D. Ceftaroline-heteroresistant Staphylococcus aureus. Antimicrob Agents Chemother: 2014; 58 6 3133 3136
109. Mendes R. E.; Tsakris A.; Sader H. S.; et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother: 2012; 67 6 1321 1324
110. Alm R. A.; McLaughlin R. E.; Kos V. N.; Sader H. S.; Iaconis J. P.; Lahiri S. D. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother: 2014; 69 8 2065 2075
111. Chong Y. P.; Park S. J.; Kim H. S.; et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis: 2012; 73 3 264 266
112. Noel G. J.; Bush K.; Bagchi P.; Ianus J.; Strauss R. S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis: 2008; 46 5 647 655
113. Johnson and Johnson Pharmaceutical Research and Development FDA Issues Complete Response Letter for Ceftobiprole. 2009. Available at: http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=433517.Accessed 17 November, 2013
114. Nicholson S. C.; Welte T.; File T. M. Jr.; et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents: 2012; 39 3 240 246
115. Awad S. S.; Rodriguez A. H.; Chuang Y. C.; et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis: 2014
116. Muller A. E.; Punt N.; Mouton J. W. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother: 2014; 58 5 2512 2519
117. Pharmaceutica B. Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia 2013. Available at: http://www.basilea.com/chameleon/public/584f9d1e-4298-e47c-0475-a5e5e5288ded/582542. Accessed December 17, 2014
118. Pharmaceutica B. Basilea to launch Zevtera/Mabelio (ceftobiprole medocaril) in Europe through a commercial services provider 2014. Available at: http://www.basilea.com/chameleon/public/87dd1a16-2523-e4d7-1ee6-1d7fe10b7b29/635582. Accessed December 17, 2014
119. Pharmaceutica B. Basilea provides update on ceftobiprole's U.S. regulatory status 2014. Available at: http://www.basilea.com/chameleon/public/de7cde4b-8150-0816-4ebb-77bfe8cb1ef5/620981 A. Accessed December 17, 2014
120. Steenbergen J. N.; Alder J.; Thorne G. M.; Tally F. P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother: 2005; 55 3 283 288
121. Boucher H. W.; Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis: 2007; 45 5 601 608
122. Gerber P.; Stucki A.; Acosta F.; Cottagnoud M.; Cottagnoud P. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother: 2006; 57 4 720 723
123. Fowler V. G. Jr, Boucher H. W.; Corey G. R.; et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med: 2006; 355 7 653 665
124. Moore C. L.; Osaki-Kiyan P.; Haque N. Z.; Perri M. B.; Donabedian S.; Zervos M. J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis: 2012; 54 1 51 58
125. Murray K. P.; Zhao J. J.; Davis S. L.; et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin. minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis: 2013; 56 1562 1569
126. Mangili A.; Bica I.; Snydman D. R.; Hamer D. H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis: 2005; 40 7 1058 1060
127. Moise P. A.; Smyth D. S.; El-Fawal N.; et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother: 2008; 61 1 85 90
128. Gould I. M.; Miró J. M.; Rybak M. J. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents: 2013; 42 3 202 210
129. Gasch O.; Camoez M.; Domínguez M. A.; et al. REIPI/GEIH study groups. Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother: 2014; 69 2 568 571
130. Humphries R. M.; Pollett S.; Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev: 2013; 26 4 759 780
131. Bayer A. S.; Schneider T.; Sahl H. G. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci: 2013; 1277 139 158
132. Howden B. P.; McEvoy C. R.; Allen D. L.; et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog: 2011; 7 11 e1002359
133. Bertsche U.; Yang S. J.; Kuehner D.; et al. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS ONE: 2013; 8 6 e67398
134. Kelley P. G.; Gao W.; Ward P. B.; Howden B. P. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother: 2011; 66 5 1057 1060
135. van Hal S. J.; Paterson D. L.; Gosbell I. B. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-a review of the literature. Eur J Clin Microbiol Infect Dis: 2011; 30 5 603 610
136. Kollef M. H.; Rello J.; Cammarata S. K.; Croos-Dabrera R. V.; Wunderink R. G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med: 2004; 30 3 388 394
137. Wunderink R. G.; Niederman M. S.; Kollef M. H.; et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis: 2012; 54 5 621 629
138. Jiang H.; Tang R. N.; Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis: 2013; 32 9 1121 1128
139. Kalil A. C.; Klompas M.; Haynatzki G.; Rupp M. E. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open: 2013; 3 10 e003912
140. Kalil A. C.; Murthy M. H.; Hermsen E. D.; Neto F. K.; Sun J.; Rupp M. E. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med: 2010; 38 9 1802 1808
141. Walkey A. J.; O'Donnell M. R.; Wiener R. S. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest: 2011; 139 5 1148 1155
142. Falagas M. E.; Manta K. G.; Ntziora F.; Vardakas K. Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother: 2006; 58 2 273 280
143. Schwalm J. D.; El-Helou P.; Lee C. H. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can J Infect Dis Med Microbiol: 2004; 15 2 97 100
144. Jang H. C.; Kim S. H.; Kim K. H.; et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis: 2009; 49 3 395 401
145. Park H. J.; Kim S. H.; Kim M. J.; et al. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect: 2012; 65 6 505 512
146. Fu J.; Ye X.; Chen C.; Chen S. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS ONE: 2013; 8 3 e58240
147. Shorr A. F.; Kunkel M. J.; Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother: 2005; 56 5 923 929
148. Locke J. B.; Zurenko G. E.; Shaw K. J.; Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis: 2014; 58 01 S35 S42
149. Shaw K. J.; Barbachyn M. R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci: 2011; 1241 48 70
150. Rodríguez-Avial I.; Culebras E.; Betriu C.; Morales G.; Pena I.; Picazo J. J. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother: 2012; 67 1 167 169
151. Thomson K. S.; Goering R. V. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother: 2013; 57 6 2892 2895
152. Prokocimer P.; De Anda C.; Fang E.; Mehra P.; Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA: 2013; 309 6 559 569
153. Das D.; Tulkens P. M.; Mehra P.; Fang E.; Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis: 2014; 58 01 S51 S57
154. Fuchs P. C.; Barry A. L.; Brown S. D. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother: 2000; 44 10 2880 2882
155. Jones R. N.; Ballow C. H.; Biedenbach D. J.; Deinhart J. A.; Schentag J. J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis: 1998; 31 3 437 451
156. Dowzicky M.; Nadler H. L.; Feger C.; Talbot G.; Bompart F.; Pease M. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med: 1998; 104 (5A): 34S 42S
157. Drew R. H.; Perfect J. R.; Srinath L.; Kurkimilis E.; Dowzicky M.; Talbot G. H. For the Synercid Emergency-Use Study Group. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother: 2000; 46 5 775 784
158. Fagon J.; Patrick H.; Haas D. W.; et al. Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med: 2000; 161 3 Pt 1 753 762
159. Berthaud N.; Montay G.; Conard B. J.; Desnottes J. F. Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia. J Antimicrob Chemother: 1995; 36 2 365 373
160. Hamel A.; Caillon J.; Jacqueline C.; Batard E.; Potel G. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. Int J Antimicrob Agents: 2008; 31 2 158 160
161. Chambers H. F. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother: 1992; 30 (Suppl A): 117 122
162. Nichols R. L.; Graham D. R.; Barriere S. L.; et al. Synercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicenter studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother: 1999; 44 2 263 273
163. Wood M. J. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother: 1996; 37 2 209 222
164. Yahav D.; Lador A.; Paul M.; Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother: 2011; 66 9 1963 1971
165. Florescu I.; Beuran M.; Dimov R.; et al. 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicenter, double-blind, randomized study. J Antimicrob Chemother: 2008; 62 01 i17 i28
166. Mendes R. E.; Sader H. S.; Deshpande L.; Jones R. N. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis: 2008; 60 4 433 436
167. Goff D. A.; Dowzicky M. J. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol: 2007; 56 Pt 9 1189 1193
168. Kaya O.; Akcam F. Z.; Temel E. N. In vitro activities of linezolid and tigecycline against methicillin-resistant Staphylococcus aureus strains. Microb Drug Resist: 2008; 14 2 151 153
169. Denis O.; Deplano A.; Nonhoff C.; et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother: 2006; 50 8 2680 2685
170. Antonopoulou A.; Tsaganos T.; Tzepi I. M.; Giamarellou H.; Giamarellos-Bourboulis E. J. Comparative efficacy of tigecycline VERSUS vancomycin in an experimental model of soft tissue infection by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin. J Chemother: 2014; Y0000000171
171. Kandemir O.; Oztuna V.; Colak M.; Akdag A.; Camdeviren H. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother: 2008; 20 1 53 57
172. Matthews P.; Alpert M.; Rahav G.; et al. Tigecycline 900 cSSSI Study Group. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. BMC Infect Dis: 2012; 12 297
173. Ramirez J.; Dartois N.; Gandjini H.; Yan J. L.; Korth-Bradley J.; McGovern P. C. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother: 2013; 57 4 1756 1762
174. Tasina E.; Haidich A. B.; Kokkali S.; Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis: 2011; 11 11 834 844
175. Prasad P.; Sun J.; Danner R. L.; Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis: 2012; 54 12 1699 1709
176. Cai Y.; Wang R.; Liang B.; Bai N.; Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother: 2011; 55 3 1162 1172
177. McGovern P. C.; Wible M.; El-Tahtawy A.; Biswas P.; Meyer R. D. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents: 2013; 41 5 463 467
178. Canut A.; Isla A.; Betriu C.; Gascón A. R. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis: 2012; 31 9 2227 2235
179. Giamarellou H.; Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol: 2011; 7 11 1459 1470
180. Bhavnani S. M.; Rubino C. M.; Hammel J. P.; et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother: 2012; 56 2 1065 1072